DSCAM and endometrial cancer: During preparation of this manuscript, in the end of 2021, a first study on the role of DSCAM-AS1 in endometrial cancer was published, which reported its upregulation in EC and its ability to downregulate the tumor-suppressive miR-136-5p [25].